S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Brickell Biotech, Inc. (BBI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.1681 |
| Open | 0.1686 |
| Bid | 0.1606 x 800 |
| Ask | 0.1649 x 1400 |
| Day's Range | 0.1600 - 0.1780 |
| 52 Week Range | 0.1600 - 1.0400 |
| Volume | |
| Avg. Volume | 5,652,500 |
| Market Cap | 18.753M |
| Beta (5Y Monthly) | 0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6240 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.67 |
- GlobeNewswire
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 study expected to be announced by early 2023 – BOULDER, Colo., May 19, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovati
- GlobeNewswire
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals (NASDAQ: IDRA) and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new expon
- GlobeNewswire
Brickell Biotech Reports First Quarter 2022Â Financial Results and Provides Corporate Update
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales Sale reflects Brickell’s new business strategy and commitment to developing its pipeline of novel, potential first-in-class treatments in immunology and inflammation On track to initiate a Phase 1 study of BBI-02, an oral DYRK1A inh
